Clinical Trials Browser

Phase 2 × Completed × lorlatinib × Clear all

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT04111705 2025-04-01

ORAKLE

Phase 2 Completed

Non Small Cell Lung Cancer Metastatic